For any others like me who are watching the patent
Post# of 1460
market: ETS (Zarontin®), VPA (Depakene®) and Gabapentin (Neurontin®)"
If AVXL is going to pursue a combo patent here, they could follow a similar process as with the Plus patent. By demonstrating SYNERGY, the FDA should allow them to patent the combinations.
PS - FU Scottsmith